Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Intangibles (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Intangibles for 16 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 91.68% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 91.68% year-over-year, with the annual reading at $1.6 million for FY2025, 91.68% down from the prior year.
  • Intangibles for Q4 2025 was $1.6 million at Anika Therapeutics, down from $15.7 million in the prior quarter.
  • The five-year high for Intangibles was $112.7 million in Q2 2021, with the low at $600000.0 in Q3 2024.
  • Average Intangibles over 5 years is $61.1 million, with a median of $74.6 million recorded in 2022.
  • The sharpest move saw Intangibles tumbled 99.46% in 2024, then skyrocketed 2522.67% in 2025.
  • Over 5 years, Intangibles stood at $82.4 million in 2021, then skyrocketed by 36.12% to $112.1 million in 2022, then crashed by 82.31% to $19.8 million in 2023, then changed by 0.0% to $19.8 million in 2024, then tumbled by 91.68% to $1.6 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $1.6 million, $15.7 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.